Regular vs Ad-lib Albuterol for Patients Hospitalized With Acute Asthma

Chandra, Alpana; Cs, Shim; Cohen, Hillel W.; Chung, Virginia; Maggiore, Diane; Mani, Kartik; Dhuper, Sunil

doi:10.1378/chest.128.3.1115

Cited by 9 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was exemplified by a small pilot study that revealed that the correlation between wheezing and peak flow was weak (43). However, in a prior study, when we studied multiple subjective symptoms, giving each symptom a severity rating, we found a reliable correlation between the cumulative severity symptom score and peak flow (44). Hence, we chose to utilize the same symptom scoring system in this study.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Cost Comparisons of Bronchodilatator Administration Between Metered Dose Inhalers with Disposable Spacers and Nebulizers for Acute Asthma Treatment

Dhuper

Chandra

Ahmed

et al. 2011

The Journal of Emergency Medicine

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Efficacy and Cost Comparisons of Bronchodilatator Administration Between Metered Dose Inhalers with Disposable Spacers and Nebulizers for Acute Asthma Treatment

Dhuper

Chandra

Ahmed

et al. 2011

The Journal of Emergency Medicine

Self Cite

View full text Add to dashboard Cite

“…The doses selected in this study were similar to recommended doses per the Ventolin ® HFA package label and are consistent with asthma treatment guidelines, the doses used for nebulization and normal clinical practice [5, 18, 22, 23]. The medications were given three times a day for 29 days as part of the study design in order to make dosing easier on the care giver and to better assess safety.…”

Section: Discussionmentioning

confidence: 99%

Safety of Daily Albuterol in Infants with a History of Bronchospasm: A Multi-Center Placebo Controlled Trial

Hedrick¹,

Baker

Atlas³

et al. 2009

TORMJ

View full text Add to dashboard Cite

Introduction:Inhaled short-acting bronchodilators are recommended for the quick relief of bronchospasm symptoms in children including those less than five years of age. However, limited safety data is available in this young population.Methods:Safety data were analyzed from a randomized, double-blind, parallel group, placebo-controlled multicenter, study evaluating albuterol HFA 90µg or 180µg versus placebo three times a day for 4 weeks using a valved holding chamber, Aerochamber Plus and facemask in children birth ≤24 months old with a history of bronchospasm.Results:The overall incidence of adverse events (AE) during treatment was: albuterol 90µg (59%), albuterol 180µg (76%) and placebo (71%). The most frequently reported AEs were pyrexia in 7 (24%), 2 (7%), and 3 (11%) subjects in the albuterol 180µg, albuterol 90µg, and placebo groups, respectively. Upper respiratory tract infection (URTI) occurred in 5 (17%) and 3 (11%) subjects in the albuterol 180µg and placebo groups, respectively. Sinus tachycardia occurred in 5 (17%), 2 (7%) and 2 (7%) subjects receiving albuterol 180µg, albuterol 90µg and placebo, respectively. One subject in each of the albuterol treatment groups experienced drug related agitation and/or restlessness or mild sinus arrhythmia. No drug-related QT prolongation or abnormal serum potassium and glucose levels were reported in the albuterol treatment groups.Conclusion:This study provides additional albuterol HFA safety information for the treatment of children aged birth ≤24 months with a history of bronchospasm.

show abstract

“…A large prospective trial 46 did not demonstrate clinical worsening of asthma when albuterol was dosed at regular intervals was compared to albuterol administration as needed. In another study 47 in adults with asthma exacerbations, the as-needed administration of albuterol was as effective as regularly scheduled administration of this drug, but the former strategy led to a shorter length of hospital stay and a lower total dose of ␤ agonist used.…”

Section: Asthmamentioning

confidence: 98%

Clinical Pharmacology of Bronchodilator Medications

Williams

Rubin

2018

Respir Care

View full text Add to dashboard Cite

Obstructive lung diseases, including asthma and COPD, are characterized by air-flow limitation. Bronchodilator therapy can often decrease symptoms of air-flow obstruction by relaxing airway smooth muscle (bronchodilation), decreasing dyspnea, and improving quality of life. In this review, we discuss the pharmacology of the β agonist and anticholinergic bronchodilators and their use, particularly in asthma and COPD. Expanding knowledge of receptor subtypes and G-protein signaling, agonist and antagonist specificity, and drug delivery have led to the introduction of safer medications with fewer off-target effects, medications with longer duration of action that may improve adherence, and more effective and efficient aerosol delivery devices.

show abstract

Regular vs Ad-lib Albuterol for Patients Hospitalized With Acute Asthma

Cited by 9 publications

References 26 publications

Efficacy and Cost Comparisons of Bronchodilatator Administration Between Metered Dose Inhalers with Disposable Spacers and Nebulizers for Acute Asthma Treatment

Efficacy and Cost Comparisons of Bronchodilatator Administration Between Metered Dose Inhalers with Disposable Spacers and Nebulizers for Acute Asthma Treatment

Safety of Daily Albuterol in Infants with a History of Bronchospasm: A Multi-Center Placebo Controlled Trial

Clinical Pharmacology of Bronchodilator Medications

Contact Info

Product

Resources

About